Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 15/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | ME2 | P23368 | 2/20 | 0.47 |
| ▸ | ME1 | P48163 | 2/20 | 0.47 |
| ▸ | ME3 | Q16798 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1903052 | 0.85 | ME2 (0.59) | GRM5CHRM1ME2ME1ME3 | |
| SCHEMBL1902534 | 0.84 | GRM5 (1.00) | GRM5 | |
| SCHEMBL1903032 | 0.82 | GRM5 (0.73) | GRM5ME2ME1ME3 | |
| SCHEMBL1902271 | 0.81 | GRM5 (0.73) | GRM5CHRM1ME2ME1ME3 | |
| SCHEMBL27736421 | 0.81 | GRM5 (0.48) | GRM5CHRM1ME2ME1ME3 | |
| SCHEMBL1901428 | 0.79 | GRM5 (0.71) | GRM5ME2ME1ME3 | |
| SCHEMBL1903008 | 0.79 | GRM5 (0.53) | GRM5ME2ME1ME3 | |
| SCHEMBL1903009 | 0.78 | GRM5 (0.81) | GRM5 | |
| SCHEMBL27736425 | 0.78 | GRM5 (0.45) | GRM5CHRM1 | |
| SCHEMBL1904981 | 0.74 | ME2 (0.58) | CHRM1ME2ME1ME3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935703-B2 | Piperazines and piperidines as Mglur5 potentiators | ASTRAZENECA AB (SE) | 2011-05-03 | — | — | US | claimed |
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | claimed |
| EP-1979320-A2 | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS | AstraZeneca AB (SE) | 2008-10-15 | — | — | EP | claimed |
| WO-2007087135-A2 | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | claimed |
| US-7935703-B2 | Piperazines and piperidines as Mglur5 potentiators | ASTRAZENECA AB (SE) | 2011-05-03 | — | — | US | disclosed |
| US-7935703-B2 | Piperazines and piperidines as Mglur5 potentiators | ASTRAZENECA AB (SE) | 2011-05-03 | — | — | US | disclosed |
| US-7935703-B2 | Piperazines and piperidines as Mglur5 potentiators | ASTRAZENECA AB (SE) | 2011-05-03 | — | — | US | disclosed |
| EP-1979320-B1 | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | GRM5, GRM1, GRIN1 | GRM5 1/4885CHRM1 51/4885ME2 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.